Compare Allstate Corp (ALL) vs Biogen Inc (BIIB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Allstate Corp vs Biogen Inc — how do they compare? Allstate Corp trades at $262 (market cap $66.31B), while Biogen Inc trades at $204 (market cap $30.13B). The key difference: Allstate Corp is far larger — about 2.2× Biogen Inc's market cap, and Allstate Corp pays a 1.65% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| ALL | BIIB | |
|---|---|---|
Market Cap | $66.31B | $30.13B |
Sector | Financials | Health |
52-Week High | $275.11 | $216.63 |
52-Week Low | $190.00 | $128.93 |
Enterprise Value | $74.96B | $37.20B |
Dividend Yield | 1.65% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Allstate Corp
On the basis of premium sales, Allstate is one of the largest U.S. property and casualty insurers. Personal auto represents the largest percentage of revenue, but the company offers homeowners insurance and other insurance products. Allstate products are sold in North America primarily by about 10,000 agencies.
Read more on ALL →About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →
